Silencing RPL11 attenuates acute kidney injury by suppressing tubular apoptosis and macrophage-driven inflammation
RPL11 drives AKI progression by orchestrating tubular dysfunction, apoptosis, and immune dysregulation. Our renal-targeted nano-intervention validates RPL11 as a therapeutically actionable target, providing a novel strategy for biomarker-guided AKI management.
Authors
- Jiang Liu (ORCID: https://orcid.org/0000-0002-4409-1157)
- Yabin Li (ORCID: https://orcid.org/0000-0002-9903-706X)
- Zhouji Shen
- Dong Qian (ORCID: https://orcid.org/0000-0002-3232-5104)
- Pengjie Xu
- Huan Xu
Institutions
- Tongji University (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fimmu.2025.1642446
- Primary Topic
- Acute Kidney Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical and Health Research Project of Zhejiang Province